194 related articles for article (PubMed ID: 12435521)
21. An evaluation of the usefulness of mycophenolate mofetil in pemphigus.
Powell AM; Albert S; Al Fares S; Harman KE; Setterfield J; Bhogal B; Black MM
Br J Dermatol; 2003 Jul; 149(1):138-45. PubMed ID: 12890207
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis.
Efe C; Hagström H; Ytting H; Bhanji RA; Müller NF; Wang Q; Purnak T; Muratori L; Werner M; Marschall HU; Muratori P; Gunşar F; Klintman D; Parés A; Heurgué-Berlot A; Schiano TD; Cengiz M; May-Sien Tana M; Ma X; Montano-Loza AJ; Berg T; Verma S; Larsen FS; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1950-1956.e1. PubMed ID: 28603052
[TBL] [Abstract][Full Text] [Related]
23. Tacrolimus and mycophenolate mofetil in pig small bowel transplantation: different protocols and their outcome.
Spada M; Alessiani M; Ferrari P; Iacona I; Abbiati F; Viezzoli A; Regazzi MB; Bellinzona G; Dionigi P; Zonta A
Transplant Proc; 1997 May; 29(3):1819-20. PubMed ID: 9142286
[No Abstract] [Full Text] [Related]
24. Mycophenolate mofetil for the management of autoimmune bullous diseases.
Eskin-Schwartz M; David M; Mimouni D
Dermatol Clin; 2011 Oct; 29(4):555-9. PubMed ID: 21924997
[TBL] [Abstract][Full Text] [Related]
25. Tolerability of mycophenolate mofetil in organ transplant recipients.
Schweizer RT; Meisterling LD
Transplant Proc; 2001 May; 33(3):2309. PubMed ID: 11377540
[No Abstract] [Full Text] [Related]
26. [Mycophenolate mofetil for induction of remission in Wegener's granulomatosis].
Kötter I
Z Rheumatol; 2007 Sep; 66(5):441-3. PubMed ID: 17717676
[No Abstract] [Full Text] [Related]
27. Interferons: unapproved uses, dosages, or indications.
Orion E; Matz H; Wolf R
Clin Dermatol; 2002; 20(5):493-504. PubMed ID: 12435520
[No Abstract] [Full Text] [Related]
28. Cyclosporine and tacrolimus in dermatology.
Cather JC; Abramovits W; Menter A
Dermatol Clin; 2001 Jan; 19(1):119-37, ix. PubMed ID: 11155577
[TBL] [Abstract][Full Text] [Related]
29. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation.
Ekberg H; van Gelder T; Kaplan B; Bernasconi C
Transplantation; 2011 Jul; 92(1):82-7. PubMed ID: 21562449
[TBL] [Abstract][Full Text] [Related]
30. Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children.
Basu B; Babu BG; Mahapatra TK
Clin Exp Nephrol; 2017 Feb; 21(1):143-151. PubMed ID: 27108294
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.
Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
Clin Chem; 2001; 47(7):1241-8. PubMed ID: 11427455
[TBL] [Abstract][Full Text] [Related]
32. Mycophenolate mofetil in autoimmune and inflammatory skin disorders.
Nousari HC; Sragovich A; Kimyai-Asadi A; Orlinsky D; Anhalt GJ
J Am Acad Dermatol; 1999 Feb; 40(2 Pt 1):265-8. PubMed ID: 10025760
[TBL] [Abstract][Full Text] [Related]
33. Tacrolimus and mycophenolate mofetil provide effective immunosuppression in rat laryngeal transplantation.
Nelson M; Fritz M; Dan O; Worley S; Strome M
Laryngoscope; 2003 Aug; 113(8):1308-13. PubMed ID: 12897551
[TBL] [Abstract][Full Text] [Related]
34. Mycophenolic acid in dermatology a century after its discovery.
Strathie Page SJ; Tait CP
Australas J Dermatol; 2015 Feb; 56(1):77-83. PubMed ID: 25557632
[TBL] [Abstract][Full Text] [Related]
35. Mizoribine versus mycophenolate mofetil in combination therapy with tacrolimus for de novo kidney transplantation: evaluation of efficacy and safety.
Ju MK; Huh KH; Park KT; Kim SJ; Cho BH; Kim CD; So BJ; Kang CM; Lee S; Joo DJ; Kim YS
Transplant Proc; 2013 May; 45(4):1481-6. PubMed ID: 23726602
[TBL] [Abstract][Full Text] [Related]
36. Antimetabolites and cytotoxic drugs.
Silvis NG
Dermatol Clin; 2001 Jan; 19(1):105-18, viii-ix. PubMed ID: 11155576
[TBL] [Abstract][Full Text] [Related]
37. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
[TBL] [Abstract][Full Text] [Related]
38. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
Kaczmarek I; Zaruba MM; Beiras-Fernandez A; Reimann R; Nickel T; Grinninger C; Sadoni S; Hagl C; Meiser B
J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
[TBL] [Abstract][Full Text] [Related]
39. Topical corticosteroids: unapproved uses, dosages, or indications.
Lagos BR; Maibach HI
Clin Dermatol; 2002; 20(5):490-2. PubMed ID: 12435519
[No Abstract] [Full Text] [Related]
40. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus.
Dean PG; Lund WJ; Larson TS; Prieto M; Nyberg SL; Ishitani MB; Kremers WK; Stegall MD
Transplantation; 2004 May; 77(10):1555-61. PubMed ID: 15239621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
